Navigation Links
Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
Date:7/16/2008

actual prostate cancer tissue and to examine the correlation between immune responses in the tissue versus those in the circulating blood."

"Given the evidence of a survival benefit seen in our previous Phase 3 trial, D9901, in patients with advanced prostate cancer, we believe PROVENGE may also have applicability to men with earlier stages of the disease. This trial will help us better understand the mechanism of action and biology of PROVENGE, as well as evaluate the potential of PROVENGE in patients at high-risk for recurrence of their cancer following radical prostatectomy," stated Mark Frohlich, M.D., senior vice president, clinical affairs and chief medical officer of Dendreon. "We are highly focused on taking the steps necessary to get PROVENGE through the FDA approval process in order to get this important immunotherapy to prostate cancer patients with advanced disease who do not have any other reasonable options. We are on track to complete the interim analysis of our ongoing Phase 3 IMPACT trial during the latter half of this year."

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 186,320 new cases expected to be diagnosed in 2008, and approximately 28,660 men expected to die this year from the disease. Currently there are limited treatment options for men with advanced, metastatic prostate cancer.

About Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined wit
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
2. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
3. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
6. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
7. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
8. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
9. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
10. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
11. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... FRANKFURT AM MAIN, Germany , ... Risk App from Merz Pharmaceuticals is available free of charge ... risk for getting dementia within the next two decades. Using ... physicians discuss preventive measures with patients at risk. ... and Incidence of DEmentia) has been developed in collaboration with ...
(Date:8/27/2014)... China, Aug. 28, 2014 China Nepstar ... or the "Company"), a leading retail drugstore chain ... operated stores, today announced its unaudited financial results ... Financial HighlightsFor the quarter ended June 30, 2014: ... million (US$110.7 million) compared to RMB638.8 million in the ...
(Date:8/27/2014)... VANCOUVER, British Columbia and MENLO ... DelMar Pharmaceuticals, Inc. , (OTCQB: DMPI), developer of ... presenting company at the 16th Annual Rodman & Renshaw ... & Co., LLC. The presentation will take place Tuesday, September ... Salon (4th floor) at the New York Palace Hotel ...
Breaking Medicine Technology:CAIDE Looks into the Future: New App from Merz Pharmaceuticals Assesses the Risk of Getting Dementia Within the Next 20 Years 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 11DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4
... (Nasdaq: PRGO ; TASE) today announced that it ... foam brought by Stiefel Research Australia Pty. Ltd., a GSK ... in the U. S., a generic version of Men,s Rogaine® ... Rogaine® (Minoxidil) Foam is used to regrow ...
... Informex , the leading meeting place for buyers ... applications, today announced details of its second Latin American Green ... The event will be held in September 2011, with further ... 2011 event follows the success of the inaugural Informex Latin ...
Cached Medicine Technology:Perrigo Announces Settlement of Rogaine® Foam Patent Litigation 2Second Annual Latin America 'Green Exchange Conference' Hosted by Informex Focuses on a Sustainable Future for Chemistry 2Second Annual Latin America 'Green Exchange Conference' Hosted by Informex Focuses on a Sustainable Future for Chemistry 3
(Date:8/28/2014)... 28, 2014 In the healthcare industry, ... practices struggle with: How can the overall quality of ... study of the healthcare industry tackles this question, and ... employee job satisfaction and the quality of patient care. ... found in “ Organizational Factors related to Improving Quality ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 DoctorBase ... and mid-sized healthcare organizations, today announced that it has ... appointment company ZocDoc , to head their sales ... has created a sales management position. , “I’m passionate ... like DoctorBase that already has so much traction and ...
(Date:8/28/2014)... York (PRWEB) August 28, 2014 An unprecedented ... and neck issues, Cloud 9 Spine offers their resources online ... problems can quickly become a brick wall of discouragement as ... a professional opinion, Cloud 9 Spine offers a ... technology merged with human interaction that sets Cloud 9 Spine ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Top ... many web hosting companies and announces Bluehost, HostMonster ... recommended suppliers for the webmasters worldwide who want ... rates. , As the world’s most popular server-side ... and many other general-purpose programs. It is now ...
(Date:8/28/2014)... Now in its 4th year, Step for ... by two brain aneurysm survivors. The ongoing mission of Step ... to help increase early detection and to help support individuals ... We hope that you will be able to join this ... Annual Step for Hope Run/ Walk on Saturday, September 6, ...
Breaking Medicine News(10 mins):Health News:New Healthcare Study Explores Strategies for Improving Patient Care 2Health News:New Healthcare Study Explores Strategies for Improving Patient Care 3Health News:New Healthcare Study Explores Strategies for Improving Patient Care 4Health News:DoctorBase Hires Josh Angeles as Vice-President of Sales 2Health News:Making Waves on the East Coast, Cloud 9 Spine is Helping Patients Find Appointments With Local Spine Doctors 2Health News:Step for Hope and Raise Brain Aneurysm Awareness 2
... arise sporadically, rather than through inheritance of certain genes, ... allow environmentally triggered mutations to accumulate, according to researchers ... Hospital of UPMC and the University of Pittsburgh Cancer ... online edition of the Proceedings of the National ...
... the emergence of an epidemic of obesity and type 2 ... that may affect the risk of metabolic diseases is especially ... tend to have about 30% lower risk of developing late ... to be at lower risk of developing metabolic syndrome ...
... Reporter , MONDAY, Nov. 29 (HealthDay News) -- The prescription ... study suggests. But one expert was quick to note ... the pain of arthritis, has been linked in some studies ... So it isn,t yet clear that Celebrex (celecoxib) is an ...
... , MONDAY, Nov. 29 (HealthDay News) -- Smoking boosts the ... and those with a genetic risk factor for rheumatoid arthritis ... a new study has found. Researchers evaluated 605 black ... found that those with the disease were slightly more likely ...
... The American College of Physicians (ACP) today is sending ... internists speaking in their own words ( ... Congress to avert the scheduled Medicare Sustainable Growth Rate ... the repeated cycle of cuts. The 3-minute and ...
... the Psychoimmunology Unit at Lund University is presenting these results ... group led by Dr Lena Brundin, which sees inflammation in ... is a new theory that challenges the prevalent view that ... serotonin and noradrenaline. "However, current serotonin-based medication cures far ...
Cached Medicine News:Health News:Sporadic breast cancers start with ineffective DNA repair systems, Pitt researchers find 2Health News:Moderate alcohol consumption lowers the risk of metabolic diseases 2Health News:Celebrex Shows Potential in Preventing Some Skin Cancers: Study 2Health News:Celebrex Shows Potential in Preventing Some Skin Cancers: Study 3Health News:Heavy Smoking May Double Rheumatoid Arthritis Risk in Blacks 2Health News:Internists issue heartfelt plea for Congress to help patients by stopping Medicare SGR cuts 2Health News:Internists issue heartfelt plea for Congress to help patients by stopping Medicare SGR cuts 3Health News:Biological changes in suicidal patients 2
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
85 right angled suture passer....
The Mini-Revo suture anchor is designed primarily for arthroscopic and open Bankart shoulder repair. Additional applications include other shoulder repair procedures, as well as use in small joints....
... Labral Anchor is an L-PLA anchor ... soft tissue reattachment to bone. The ... bony contour of the glenoid, optimizing ... Osteo Compression (ROC) design to provide ...
Medicine Products: